🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

33+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 13 of 33 recruiting trials for “aggressive-nk-cell-leukemia”

Phase 2RecruitingNCT06244368 ↗

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

👨‍⚕️ Wei Liu, Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC📍 1 site📅 Started Jan 2024View details ↗
Phase 1RecruitingNCT06180174 ↗

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

👨‍⚕️ Yuqin Song, M.D, Peking University Cancer Hospital & Institute📍 1 site📅 Started Dec 2023View details ↗
Phase 1, PHASE2RecruitingNCT05863234 ↗

Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia

🏥 Hiroshima University Hospital📍 1 site📅 Started Sep 2023View details ↗
Phase 3RecruitingNCT05820841 ↗

Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma

👨‍⚕️ Konstantinos Christofyllakis, MD MSc, Saarland University Medical Center📍 17 sites📅 Started Jun 2023View details ↗
Phase 1, PHASE2RecruitingNCT05826535 ↗

Study of LYL314 in Aggressive Large B-Cell Lymphoma

🏥 Lyell Immunopharma, Inc.📍 28 sites📅 Started May 2023View details ↗
Phase 2RecruitingNCT05941156 ↗

Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia

🏥 The Affiliated Hospital of Xuzhou Medical University📍 1 site📅 Started May 2023View details ↗
Phase 1RecruitingNCT05685173 ↗

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

👨‍⚕️ Clinical Trial Management, Regeneron Pharmaceuticals📍 20 sites📅 Started Apr 2023View details ↗
Phase 1RecruitingNCT05412290 ↗

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

👨‍⚕️ Armin Ghobadi, M.D., Washington University School of Medicine📍 1 site📅 Started Dec 2022View details ↗
Phase 2RecruitingNCT05281809 ↗

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

👨‍⚕️ John Lister, MD, AHN📍 1 site📅 Started Apr 2022View details ↗
Phase 1RecruitingNCT04884035 ↗

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

👨‍⚕️ Bristol-Myers Squibb, Bristol-Myers Squibb📍 40 sites📅 Started Sep 2021View details ↗
Phase 1RecruitingNCT04231877 ↗

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

👨‍⚕️ Ryan Lynch, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Oct 2020View details ↗
EARLY_Phase 1RecruitingNCT04161248 ↗

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

👨‍⚕️ Sarit Assouline, The Jewish General Hospital, Montreal QC, Canada📍 4 sites📅 Started Sep 2020View details ↗
Phase 1RecruitingNCT01853631 ↗

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

👨‍⚕️ Carlos A Ramos, MD, Baylor College of Medicine📍 2 sites📅 Started Feb 2014View details ↗
← PreviousPage 2 of 2

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →